Biomarkers Role in Development of VEGF Inhibitors Discussed in Biopharm Reports Study Available at MarketPublishers.com03 Sep 2013 • by Natalie Aster
LONDON – Since the discovery of vascular endothelial growth factor (VEGF) nearly 30 years ago, numerous clinical studies have been carried out to identify how the blocking of VEGF might slow or stop the growth of tomours, which require a blood supply to survive and expand. To date, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many types of cancer, including colorectal and non-small cell lung cancer. Whereas VEGF inhibitors like bevacizumab (Avastin®) provide valuable treatment options, these benefits, though, are not observed in all cancers and patients. To this end, it is critical to identify those patients who are likely to benefit, particularly as these agents can be toxic and are expensive.
In-demand research report “VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013” elaborated by Biopharm Reports offers a comprehensive guide to various biomarkers associated with antiangiogenic therapy is in its early stages.
The study reviews a number of clinical studies in which various biomarkers have been identified and explained – either therapy-indicating with respect to bevacizumab (Avastin®) and VEGF-related biomarkers, or indicative of patient prognosis. The report identifies the most important findings for their significance and value to patients and in designing clinical trials. The research provides the latest findings on ten different kinds of cancer and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria. An evaluation of existing bevacizumab-containing treatments and drug combinations is provided, too.
VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
Published: February, 2013
Price: US$ 1,492.00
More in-demand studies by the publisher can be found at Biopharm Reports page.